Cargando…

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy

Blockade of the PD-1/PD-L1 immunologic checkpoint using monoclonal antibodies has provided breakthrough therapies against cancer in the recent years. Nevertheless, intrinsic disadvantages of therapeutic antibodies may limit their applications. Thus, blocking of the PD-1/PD-L1 interaction by small mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fengling, Ye, Wenling, Wang, Shuang, He, Yongxing, Zhong, Haiyang, Wang, Yuwei, Zhu, Yongchang, Han, Jianting, Bing, Zhitong, Ji, Shaoping, Liu, Huanxiang, Yao, Xiaojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851350/ https://www.ncbi.nlm.nih.gov/pubmed/33529880 http://dx.doi.org/10.1016/j.neo.2021.01.001

Ejemplares similares

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction
por: Wang, Fengling, et al.
Publicado: (2023)

Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship
por: Shi, Danfeng, et al.
Publicado: (2019)

Discovery of pentapeptide-inhibitor hits targeting FKBP51 by combining computational modeling and X-ray crystallography
por: Han, Jian-Ting, et al.
Publicado: (2021)

Insights into the molecular mechanism of positive cooperativity between partial agonist MK-8666 and full allosteric agonist AP8 of hGPR40 by Gaussian accelerated molecular dynamics (GaMD) simulations
por: An, Xiaoli, et al.
Publicado: (2021)

Binding Thermodynamics and Dissociation Kinetics Analysis Uncover the Key Structural Motifs of Phenoxyphenol Derivatives as the Direct InhA Inhibitors and the Hotspot Residues of InhA
por: Zhang, Qianqian, et al.
Publicado: (2022)

Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening
por: Ge, Huizhen, et al.
Publicado: (2022)

Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors
por: Xue, Weiwei, et al.
Publicado: (2014)

Computational Study on the Inhibitor Binding Mode and Allosteric Regulation Mechanism in Hepatitis C Virus NS3/4A Protein
por: Xue, Weiwei, et al.
Publicado: (2014)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
por: Long, Junyu, et al.
Publicado: (2017)

PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond
por: Ishida, Yasumasa
Publicado: (2020)

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
por: Liu, Hao, et al.
Publicado: (2022)

Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab
por: Ye, Wenling, et al.
Publicado: (2023)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
por: Xiao, Weiwei, et al.
Publicado: (2023)

Quantitative proteomic analysis for radiation-induced cell cycle suspension in 92-1 melanoma cell line
por: Wang, Fengling, et al.
Publicado: (2013)

Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening
por: Wang, Yuwei, et al.
Publicado: (2020)

Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma
por: Peng, Xiaopeng, et al.
Publicado: (2023)

A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
por: Kong, Xianbin, et al.
Publicado: (2021)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Proteomic analysis of effects by x-rays and heavy ion in HeLa cells
por: Bing, Zhitong, et al.
Publicado: (2014)

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
por: Liu, Hao, et al.
Publicado: (2019)

Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor
por: Li, Qiao, et al.
Publicado: (2016)

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
por: Yao, Han, et al.
Publicado: (2018)

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
por: Luke, Jason J., et al.
Publicado: (2015)

Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy
por: El Bitar, Sandy, et al.
Publicado: (2018)

Exploring the Influence of EGCG on the β-Sheet-Rich Oligomers of Human Islet Amyloid Polypeptide (hIAPP(1–37)) and Identifying Its Possible Binding Sites from Molecular Dynamics Simulation
por: Wang, Qianqian, et al.
Publicado: (2014)

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
por: Sun, Chengliang, et al.
Publicado: (2022)

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
por: Zhu, Zhouting, et al.
Publicado: (2023)

Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
por: Yan, Zheng, et al.
Publicado: (2021)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
por: Abdin, Shifaa M., et al.
Publicado: (2018)

PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance
por: Wang, Yuanqiang, et al.
Publicado: (2019)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
por: Guo, Liting, et al.
Publicado: (2017)

Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy
por: Chen, Fei, et al.
Publicado: (2022)

Neodb: a comprehensive neoantigen database and discovery platform for cancer immunotherapy
por: Wu, Tao, et al.
Publicado: (2023)

A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model
por: Wei, Yuhua, et al.
Publicado: (2022)

Deciphering the Effect of Lysine Acetylation on the Misfolding and Aggregation of Human Tau Fragment (171)IPAKTPPAPK(180) Using Molecular Dynamic Simulation and the Markov State Model
por: Shah, Syed Jawad Ali, et al.
Publicado: (2022)

Effects of the Pathogenic Mutation A117V and the Protective Mutation H111S on the Folding and Aggregation of PrP106-126: Insights from Replica Exchange Molecular Dynamics Simulations
por: Ning, Lulu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pl0tvf0btv0n1tglu3l3qc33eo